Why the study?
Does nanoparticle-mediated delivery of pitavastatin reduce post-infarct left ventricular remodeling in a mouse model of myocardial infarction?
Does nanoparticle-mediated delivery of pitavastatin reduce post-infarct left ventricular remodeling in a mouse model of myocardial infarction?
Nanoparticle-mediated delivery of pitavastatin to monocytes/macrophages attenuates post-infarct LV remodeling in mice, suggesting a novel therapeutic strategy for post-MI heart failure.
Answers are grounded in this paper and cite their sources.
Pitavastatin-NPs may target post-MI inflammation in models; leaves open translation to human remodeling therapy.
Left ventricular (LV) remodeling after myocardial infarction (MI) causes heart failure. Although medical therapies including angiotensin converting enzyme inhibitors show inhibitory effects on post-infarct LV remodeling, the prognosis of patients with post-infarct heart failure is still poor. Accumulating evidence suggests that an inflammatory response is implicated in the process of post-infarct LV remodeling. Therefore, we hypothesized that anti-inflammatory therapy by nanoparticle-mediated monocyte/macrophage-targeting delivery of pitavastatin may protect the heart from post-infarct LV remodeling.Male C57BL/6 mice were subjected to permanent coronary ligation and pitavastatin-incorporating nanoparticles (Pitavastatin-NPs) were intravenously injected for 3 to 5 consecutive days. Pitavastatin-NPs were delivered to CD11b⁺ monocytes/macrophages, but not to cardiomyocytes. Treatment with Pitavastatin-NPs after establishment of MI attenuated post-infarct LV remodeling accompanied by a reduction of monocytes/macrophages in the heart, whereas pitavastatin solution treatment did not. Pitavastatin-NPs inhibited mobilization of monocytes from the spleen after MI. In mice after splenectomy, Pitavastatin-NPs still decreased the number of monocytes/macrophages in the infarcted heart and inhibited post-infarct LV remodeling.Nanoparticle-mediated delivery of pitavastatin to monocytes/macrophages may be a novel therapeutic strategy to protect the heart from post-infarct LV remodeling. Inhibition of monocyte mobilization from the bone marrow is one of the major mechanisms by which Pitavastatin-NPs attenuated post-infarct LV remodeling.
No takes yet. Share an insight, caveat, or question.
Mao et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: